drugset / Trial / NCT01218620
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase I trial studies the side effects and best dose of RO4929097 in treating patients with advanced solid tumors. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-07
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dextromethorphan | Unknown | — | Oral |
| Subject | Ketoconazole | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Intravenous |
| Subject | Omeprazole | Other / unclassified | — | Oral |
| Subject | RG4733 | Small molecule | 20 mg | Oral |
| Subject | RG4733 | Small molecule | 50 mg | Oral |
| Subject | Rifampin | Small molecule | — | Oral |
| Subject | Tolbutamide | Small molecule | — | Oral |